Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care

Journal of Visualized Experiments

Volumn , Issue 96, 2015, Pages

  Riccione, Katherine ^a,b   Suryadevara, Carter M ^a   Snyder, David ^a   Cui, Xiuyu ^a   Sampson, John H ^a,b   Sanchez Perez, Luis ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Duke University   (United States)

Author keywords

Adoptive transfer; Chimeric antigen receptor; Glioblastoma; Immunology; Issue 96; Radiotherapy; Temozolomide; Tumor immunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; FEMALE; GENE VECTOR; GENETICS; GLIOBLASTOMA; HEALTH CARE QUALITY; IMMUNOLOGY; MOUSE; PROCEDURES; T LYMPHOCYTE;

ANIMALS; BRAIN NEOPLASMS; FEMALE; GENETIC VECTORS; GLIOBLASTOMA; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; STANDARD OF CARE; T-LYMPHOCYTES;

EID: 84923553822     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52397     Document Type: Article

References (37)

1. Stupp, R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352, (10), 987-996 (2005).
2. Kantoff, P., Higano, C., Shore, N., Berger, E., Small, E. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. (363), 411-422 (2010).
3. Hodi, F. S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, (8), 711-723 (2010).
4. Schwartzentruber, D. J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 364, (22), 2119-2127 (2011).
5. Gross, G., Gorochov, G., Waks, T., Eshhar, Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 21, (1 Pt 1), 127-130 (1989).
6. Pule, M. A., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 14, (11), 1264-1270 (2008).
7. Kochenderfer, J. N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119, (12), 2709-2720 (2012).
8. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 365, (8), 725-733 (2011).
9. Brentjens, R. J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118, (18), 4817-4828 (2011).
10. Wikstrand, C. J., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, (14), 3140-3148 (1995).
11. Sampson, J. H., et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 20, (4), 972-984 (2014).
12. Kuppner, M. C., Hamou, M. F., Sawamura, Y., Bodmer, S., de Tribolet, N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg. 71, (2), 211-217 (1989).
13. Wintterle, S., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63, (21), 7462-7467 (2003).
14. Fecci, P. E., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, (6), 3294-3302 (2006).
15. Wilmotte, R., et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 16, (10), 1081-1085 (2005).
16. Yang, B. C., et al. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by fas signaling through a protein kinase A-independent pathway. Journal of Immunology. 171, (8), 3947-3954 (2003).
17. Reilly, S. M., et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 29A, (7), 940-942 (1993).
18. Newcomb, E., et al. The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261Gliomas. Clin Cancer Res. 12, 4730-4737 (2006).
19. Park, B., Yee, C., Lee, K. M. The effect of radiation on the immune response to cancers. Int J Mol Sci. 15, (1), 927-943 (2014).
20. Fritzell, S., et al. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunol Immunother. 62, (9), 1463-1474 (2013).
21. Park, S. D., et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine. 25, (17), 3485-3491 (2007).
22. Emens, L. A., Jaffee, E. M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, (18), 8059-8064 (2005).
23. Murphy, K. A., et al. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res. 18, (17), 4657-4668 (2012).
24. Newcomb, E. W., et al. Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res. 173, (4), 426-432 (2010).
25. Su, Y. B., Krown, S. E., Livingston, P. O., Wolchok, J. D., Chapman, P. B. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 23, (18), 4235-4236 (2005).
26. Neyns, B., Tosoni, A., Hwu, W. J., Reardon, D. A. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 116, (12), 2868-2877 (2010).
27. Muranski, P., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go. Nat Clin Pract Oncol. 3, (12), 668-681 (2007).
28. Wrzesinski, C., Restifo, N. P. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Current Opinion in Immunology. 17, (2), 195-201 (2005).
29. Dudley, M. E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 26, (32), 5233-5239 (2008).
30. Sanchez-Perez, L. A., et al. Myeloablative Temozolomide Enhances CD8(+) T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. Plos One. 8, (3), (2013).
31. Su, Y. B., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 22, (4), 610-616 (1200).
32. Dummer, W., et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 110, (2), 185-192 (2002).
33. Gattinoni, L., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 202, (7), 907-912 (2005).
34. Wrzesinski, C., et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 33, (1), 1-7 (2010).
35. Hughes, M. S., et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 16, (4), 457-472 (2005).
36. Morgan, R. A., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 23, (10), 1043-1053 (2012).
37. Kerkar, S. P., et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother. 34, (4), 343-352 (2011).